Histone deacetylase inhibitor MS-275 exhibits poor brain penetration: Pharmacokinetic studies of [11C]MS-275 using positron emission tomography

ACS Chemical Neuroscience

Volumn 1, Issue 1, 2010, Pages 65-73

  Hooker, Jacob M ^a   Kim, Sung Won ^a,b   Alexoff, David ^a   Xu, Youwen ^a   Shea, Colleen ^a   Reid, Alicia ^a,c   Volkow, Nora ^a,b,d   Fowler, Joanna S ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Brain; Carbon 11; Entinostat; Epigenetics; HDAC; Histone deacetylase; MS 275; PET

Indexed keywords

CARBON 11; HISTONE DEACETYLASE INHIBITOR; MS 275 CARBON 11; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BABOON; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; EXPERIMENTAL MODEL; FEMALE; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT;

PRIMATES; RODENTIA;

EID: 77952170915     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn9000268     Document Type: Article

References (32)

1. Minucci, S., and Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51.
2. Papait, R., Monti, E., and Bonapace, I. M. (2009) Novel approaches on epigenetics. Curr. Opin. Drug Discovery Dev. 12, 264-275.
3. Acharya, M. R., Sparreboom, A., Venitz, J., and Figg, W. D. (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 68, 917-932.
4. Saito, A.,Yamashita, T., Mariko, Y.,Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 96, 4592-4597.
5. Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., and Nakanishi, O. (1999) Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42, 3001-3003.
6. Chen, Y. D., Jiang, Y. J., Zhou, J. W., Yu, Q. S., and You, Q. D. (2008) Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J. Mol. Graphics Model. 26, 1160-1168.
7. Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., Steinkuhler, C., and Di Marco, S. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U.S.A. 101, 15064-15069.
8. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., Finn, P.W., Collins, L. S., Tumber, A., Ritchie, J.W., Jensen, P. B., Lichenstein, H. S., and Sehested, M. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409, 581-589.
9. Hauschild, A., Trefzer, U., Garbe, C., Kaehler, K. C., Ugurel, S., Kiecker, F., Eigentler, T., Krissel, H., Schott, A., and Schadendorf, D. (2008) Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 18, 274-278.
10. Kazantsev, A. G., and Thompson, L. M. (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discovery 7, 854-868.
11. Thomas, E. A. (2009) Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol. Neurobiol. 40, 33-45.
12. Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H., Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., Mazitschek, R., Bradner, J. E., DePinho, R. A., Jaenisch, R., and Tsai, L. H. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60.
13. Stefanko, D. P., Barrett, R. M., Ly, A. R., Reolon, G. K., and Wood, M. A. (2009) Modulation of long-term memory for object recognition via HDAC inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 9447-9452.
14. Hahnen, E., Eyupoglu, I. Y., Brichta, L., Haastert, K., Trankle, C., Siebzehnrubl, F. A., Riessland, M., Holker, I., Claus, P., Romstock, J., Buslei, R., Wirth, B., and Blumcke, I. (2006) In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 98, 193-202.
15. Siebzehnrubl, F. A., Buslei, R., Eyupoglu, I. Y., Seufert, S., Hahnen, E., and Blumcke, I. (2007) Histone deacetylase inhibitors increase neuronal differentiation in adult forebrain precursor cells. Exp. Brain Res. 176, 672-678.
16. Gavin, D. P., Rosen, C., Chase, K., Grayson, D. R., Tun, N., and Sharma, R. P. (2009) Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures. J. Psychiatry Neurosci. 34, 232-237.
17. Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., and Winrow, C. J. (2007) Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci. 31, 47-58.
18. Allen Brain Atlas: http://www.allenbrainatlas.com.
19. Reid, A. E., Hooker, J., Shumay, E., Logan, J., Shea, C., Kim, S. W., Collins, S., Xu, Y., Volkow, N., and Fowler, J. S. (2009) Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. Nucl. Med. Biol. 36, 247-258.
20. Simonini, M. V., Camargo, L. M., Dong, E., Maloku, E., Veldic, M., Costa, E., and Guidotti, A. (2006) The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 103, 1587-1592.
21. Eyupoglu, I. Y., Hahnen, E., Trankle, C., Savaskan, N. E., Siebzehnrubl, F. A., Buslei, R., Lemke, D., Wick, W., Fahlbusch, R., and Blumcke, I. (2006) Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol. Cancer Ther. 5, 1248-1255.
22. Holsken, A., Eyupoglu, I. Y., Lueders, M., Trankle, C., Dieckmann, D., Buslei, R., Hahnen, E., Blumcke, I., and Siebzehnrubl, F. A. (2006) Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol. 112, 205-215.
23. Hooker, J. M., Reibel, A. T., Hill, S. M., Schueller, M. J., and Fowler, J. S. (2009) One-pot, direct incorporation of [11C]CO2 into carbamates. Angew. Chem., Int. Ed. 48, 3482-3485.
24. Gediya, L. K., Belosay, A., Khandelwal, A., Purushottamachar, P., and Njar, V. C. (2008) Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg. Med. Chem. 16, 3352-3360.
25. Dischino, D. D., Welch, M. J., Kilbourn, M. R., and Raichle, M. E. (1983) Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24, 1030-1038.
26. Acharya, M. R., Sparreboom, A., Sausville, E. A., Conley, B. A., Doroshow, J. H., Venitz, J., and Figg, W. D. (2006) Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother. Pharmacol. 57, 275-281.
27. Chen, X., Zhou, Z. W., Xue, C. C., Li, X. X., and Zhou, S. F. (2007) Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 37, 635-678.
28. Yu, X. Y., Lin, S. G., Zhou, Z. W., Chen, X., Liang, J., Yu, X. Q., Chowbay, B., Wen, J. Y., Duan, W., Chan, E., Li, X. T., Cao, J., Li, C. G., Xue, C. C., and Zhou, S. F. (2007) Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra. Pharm. Res. 24, 1668-1690. (Pubitemid 47206618)
29. Ejsing, T. B., Hasselstrom, J., and Linnet, K. (2006) The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol. Drug Interact. 21, 139-162.
30. Kummar, S., Gutierrez, M., Gardner, E. R., Donovan, E., Hwang, K., Chung, E. J., Lee, M. J., Maynard, K., Kalnitskiy, M., Chen, A., Melillo, G., Ryan, Q. C., Conley, B., Figg, W. D., Trepel, J. B., Zwiebel, J., Doroshow, J. H., and Murgo, A. J. (2007) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 13, 5411-5417.
31. Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., and Eckhardt, S. G. (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14, 4517-4525.
32. Alexoff, D. L., Shea, C., Fowler, J. S., King, P., Gatley, S. J., Schlyer, D. J., and Wolf, A. P. (1995) Plasma input function determination for PET using a commercial laboratory robot. Nucl. Med. Biol. 22, 893-904.